Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | USP14 | P54578 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2693344 | 0.85 | KCNA3 (0.54) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL7586943 | 0.84 | CTSK (0.51) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL15373110 | 0.83 | KCNA3 (0.52) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL27460572 | 0.82 | CTSK (0.55) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL3965693 | 0.82 | CTSK (0.55) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL15297799 | 0.82 | KCNA3 (0.51) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL18175702 | 0.82 | CTSK (0.49) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL13255982 | 0.81 | CTSK (0.54) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL1525518 | 0.81 | CTSK (0.57) | CTSKKCNA3BTKUSP14DRD2 | |
| SCHEMBL26785048 | 0.81 | CTSK (0.54) | CTSKKCNA3BTKUSP14DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
| EP-2389376-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basilea Pharmaceutica AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| WO-2010084152-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | CTSK 2282/4885KCNA3 546/4885BTK 860/4885 |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | CTSK 2263/4885KCNA3 643/4885BTK 1432/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | CTSK 2263/4885KCNA3 643/4885BTK 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.